David Jablons, MD Professor and Chief Division of General Thoracic Surgery Ada Distinguished Professor and Program Leader Thoracic Oncology UCSF Helen Diller Family Comprehensive Cancer Center University of California, San Francisco San Francisco, California
	Click here to download entire interview
Track 1	Intergroup 0139 trial and the controversial role of surgery in the multimodality treatment of patients with Stage III non-small cell lung cancer (NSCLC)
Track 2	Case discussion: A 60-year-old former smoker with asymptomatic Stage IIIA adenocarcinoma of the lung
Track 3	Induction chemotherapy as an in vivo test of chemosensitivity
Track 4	Applying translational preoperative models in NSCLC to identify predictors of response and develop individually tailored therapeutic approaches
Track 5	Evolution from “Jurassic Park Surgery” to minimally invasive thoracotomy
Track 6	Pulmonary hypertensive crisis associated with right-sided pneumonectomy
Track 7	Factors affecting outcome from pneumonectomy
Track 8	Induction cisplatin/pemetrexed with radiation therapy for Stage III adenocarcinoma of the lung
Track 9	Clinical considerations in the selection of postoperative adjuvant systemic therapy
Track 10	Incorporation of molecular predictors of response in the selection of adjuvant chemotherapy for early-stage NSCLC
Track 11	Biomarker assessment and clinical decision-making in early-stage NSCLC
Track 12	Excision repair cross-complementing 1 (ERCC1) gene in clinical decision-making for NSCLC
Track 13	A thoracic oncologist’s perspective on the surgeon’s role in lung cancer management
Track 14	Challenges in the surgical management of mesothelioma
Track 15	Cancer stem cell-specific therapeutic approaches: Hedgehog, Notch and Wnt signaling pathways

Gregory J Riely, MD, PhD Assistant Attending Memorial Sloan-Kettering Cancer Center New York, New York
	Click here to download entire interview
Track 1	Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors (TKIs)
Track 2	Single-agent activity of EGFR monoclonal antibodies in NSCLC
Track 3	EGFR protein expression, gene amplification and mutation status as predictors of response to EGFR TKIs
Track 4	Barriers to routine performance of EGFR mutation testing
Track 5	Adjuvant clinical trials in lung cancer for patients with tumors containing EGFR mutations
Track 6	Decisional analysis in offering adjuvant erlotinib off protocol to patients with EGFR mutations
Track 7	EGFR TKI-associated interstitial lung disease
Track 8	Use of first-line erlotinib with or without chemotherapy in select patients with advanced NSCLC
Track 9	FLEX: Cetuximab with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of advanced NSCLC
Track 10	K-ras mutation as a predictor of primary resistance to EGFR TKIs and monoclonal antibodies in NSCLC
Track 11	Utilization of K-ras and EGFR mutation status in clinical decision-making for NSCLC
Track 12	Tradeoffs with cetuximab/chemotherapy as first-line therapy for advanced squamous cell carcinoma of the lung
Track 13	Risks and benefits of carboplatin/paclitaxel and bevacizumab for advanced NSCLC
Track 14	Continuation of EGFR TKIs after disease progression
Track 15	Increased EGFR gene copy number via FISH predicts outcomes for patients with NSCLC treated with cetuximab/chemotherapy: Clinical implications of SWOG-S0342
Track 16	Prediction of response to erlotinib in patients with bronchoalveolar carcinoma (BAC) or adenocarcinoma with BAC features
Track 17	Phase I/II trial of weekly nanoparticle albumin-bound (nab) paclitaxel as initial chemotherapy for Stage IV NSCLC
Track 18	Maintenance pemetrexed for patients with Stage IIIB/IV NSCLC who had not experienced disease progression on platinum-based induction chemotherapy
Track 19	Nonsquamous cell histology and benefit from first-line cisplatin and pemetrexed in advanced NSCLC
Track 20	Carboplatin/pemetrexed and bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced nonsquamous NSCLC
Track 21	Investigational agents with dual targeting of EGFR and VEGF in NSCLC

Alan B Sandler, MD Associate Professor of Medicine Medical Director, Thoracic Oncology Vanderbilt University Medical Center Division of Hematology/Oncology Nashville, Tennessee
	Click here to download entire interview
Track 1	Clinical considerations in the use of first-line chemotherapy/cetuximab in patients with EGFR-overexpressing advanced NSCLC
Track 2	ECOG-E4599: Outcome from first-line carboplatin/paclitaxel with bevacizumab in advanced, nonsquamous cell NSCLC: Analysis of age and gender
Track 3	Predictors of bevacizumab-related hemoptysis in ECOG-E4599
Track 4	AVAiL: A Phase III study of first-line cisplatin/gemcitabine with or without bevacizumab in advanced or recurrent nonsquamous NSCLC
Track 5	Potential for differential efficacy of chemotherapy/bevacizumab combinations
Track 6	Rationale for continuation of bevacizumab upon disease progression
Track 7	Ongoing clinical trials in lung cancer evaluating nab paclitaxel
Track 8	Efficacy of bevacizumab in combination with chemotherapy or erlotinib in patients with previously treated advanced NSCLC
Track 9	Studies of the multikinase inhibitor vandetanib in NSCLC
Track 10	ECOG-E1505: A Phase III study of adjuvant chemotherapy with or without bevacizumab in Stage IB-IIIA NSCLC
Track 11	Individualization of adjuvant lung cancer therapy
Track 12	Pemetrexed/carboplatin versus etoposide/carboplatin for extensive-stage small cell lung cancer (SCLC)

David S Ettinger, MD Alex Grass Professor of Oncology The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland
	Click here to download entire interview
Track 1	Histology and treatment decision-making in lung cancer
Track 2	Implication of the FLEX data for bevacizumab-ineligible patients with previously untreated advanced NSCLC
Track 3	Ramping up biomarker assessment and personalized medicine in NSCLC
Track 4	Clinical trials evaluating chemoradiation therapy and cetuximab for locally advanced NSCLC
Track 5	Role of maintenance therapy in Stage III NSCLC
Track 6	Development of the novel anthracycline amrubicin in SCLC
Track 7	“Rule out five” approach for carcinoma of unknown primary